Cardiovascular toxicity of fluoropirymidines
- Authors: Kolomiets E.A1, Besova N.S1, Kurmukov I.A1, Kashia S.R1, Narimanov M.N1, Sandomirskaya A.P1
-
Affiliations:
- FSBI NMRC of Oncology n.a. N.N. Blokhin of RMH
- Issue: No 18 (2017)
- Pages: 76-79
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/290024
- ID: 290024
Cite item
Abstract
Full Text
About the authors
E. A Kolomiets
FSBI NMRC of Oncology n.a. N.N. Blokhin of RMH
Email: dr.kolomiets@mail.ru
cardiologisT., an advisory group of the Department of Hospital Therapy and Functional Diagnostics of the Department of Functional Diagnostics, Intensive Care and Rehabilitation
N. S Besova
FSBI NMRC of Oncology n.a. N.N. Blokhin of RMH
I. A Kurmukov
FSBI NMRC of Oncology n.a. N.N. Blokhin of RMH
Sh. R Kashia
FSBI NMRC of Oncology n.a. N.N. Blokhin of RMH
M. N Narimanov
FSBI NMRC of Oncology n.a. N.N. Blokhin of RMH
A. P Sandomirskaya
FSBI NMRC of Oncology n.a. N.N. Blokhin of RMH
References
- Marwick T.H. Cancer Therapy-Related Cardiac Dysfunction: Unresolved Issues. Can. J. Cardiol. 2016;32:842-46.
- Layoun M.E., Wickramasinghe C.D., Peralta M.V., Yang E.H. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management © Springer Science+Business Media New York. 2016.
- Lokich J.J. Infusional 5-FU: historical evolution, rationale, and clinical experience. Oncology. 1998;12:19-22.
- Anand A. Fluorouracil cardiotoxicity. Ann. Pharmacother. 1994;28:374.
- Akhtar S., Salim K., Bano Z. Symptomatic cardiotoxicity with high dose 5-fluorouracil infusion: a prospective study. Oncology. 1993;50:441.
- Wacker A., Lersch C., Scherpinski U., Reindl L., Seyfarth M. High incidence of angina pectoris in patients treated with 5-fluorouracil: a planned surveillance study with 102 patients. Oncology. 2003;65(2):108-12.
- Lamberti M., Porto S., Zappavigna S., Addeo E., Marra M., Miraglia N., Sannolo N., Vanacore D., Stiuso P., Caraglia M. A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives. Toxicol Lett. 2014;227(3):151-56.
- Polk A., Vaage-Nilsen M., Vistisen K., Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat. Rev. 2013;39(8):974-84.
- Suter T.M., Ewer M.S. Cancer drugs and the heart: importance and management. Eur. Heart J. 2013;34:1102-11.
- Labianca R., Beretta G., Clerici M., Fraschini P., Luporini G. Cardiac toxicity of 5-FU: a study of 1,083 patients. Tumori. 1982;68:505-10.
- De Forni M. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J. Clin. Oncol. 1992;10(11): 1795-801.
- Meyer C.C., Calis K.A., Burke L.B., Walawander C.A., Grasela T.H. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy. 1997;17(4):729-36.
- Khichina E., Kashiya S., Sandomirskaya A., Kurmukov I., Obukhova O., Davydova L., Goncharova Y. European Journal of Preventive Cardiology. 2017;24(Suppl. 1):26-7.
- Кашия Ш.Р, Курмуков И.А., Гончарова Ю.К., Зипалова Л.В., Хичина Е.А. Распространенность сердечно-сосудистой патологии у онкологических больных, получающих противоопухолевое лекарственное лечение в специализированном стационаре. Злокачественные опухоли. 2016; 4(Suppl.1, 20):275.
- Jensen S.A., Sаrensen J.B. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother. Pharmacol. 2006;58(4):487-93.
- Becker K., Erckenbrecht J.F., Haussinger D., et al. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs. 1999;57:475-84.
- Sorrentino M.F., KimJ.,Foderaro A.E., Truesdell A.G. 5-fluorouracil induced cardiotoxicity: review of the literature. Cardiol. J. 2012;19(5):453-58.
- Ng M., Cunningham D., Norman A.R. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur. J. Cancer 2005;41:1542-46.
- Lamberti M., Porto S., Marra M., Zappavigna S., Grimaldi A., Feola D., Pesce D., Naviglio S., Spina A., Sannolo N., Caraglia M. 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress. J. Exp. Clin. Cancer Res. 2012;31:60-10.
- Durak I., Karaayvaz M., Kavutcu M., Cimen M.Y., Kacmaz M., Buyukkocak S., Ozturk HS. Reduced antioxidant defense capacity in myocardial tissue from guinea pigs treated with 5-fluorouracil. J. Toxicol. Environ. Health A. 2000;59:585-89.
- Schöber C., Papageorgiou E., Harstrick A., Bokemyer C., Mügge A., Stahl M. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993;72:2242-47.
- Daher I.N., Yeh E.T. Vascular complications of selected cancer therapies. Nat. Clin. Pract. Cardiovasc. Med. 2008;5:797-805.
- Soultati A., Mountzios G., Avgerinou C., Papaxoinis G., Pectasides D., Dimopoulos M.A., Papadimitriou C. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat. Rev. 2012;38:473-83.
- Cameron A.C., Touyz R.M., Lang N.N. Vascular Complications of Cancer Chemotherapy (Review). Can. J. Cardiol. 2016;32:852-62.
- Alter P., Herzum M., Soufi M., Schaefer J.R., Maisch B. Cardiotoxicity of 5-fluorouracil. Cardiovasc. Hematol. Agents Med. Chem. 2006;4:1-5.
- Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004;350:2335-42.
- Meinardi M.T., Gietema J.A., van Veldhuisen D.J., van der Graaf W.T., de Vries E.G., Sleijfer D.T. Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat. Rev. 2000;26:429-47.
- Polk A., Vistisen K., Vaage-Nilsen M., Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC. Pharmacol. Toxicol. 2014;15:47.
- David J.S., Gueugniaud P.Y., Hepp A., Gaussorgues P., Petit P. Severe heart failure secondary to 5-fluorouracil and low-doses of folinic acid: usefulness of an intra-aortic balloon pump. Crit. Care Med. 2000;28(10):3558-60.
- Höllriegel R., Fischer J., Schuler G. Early extracorporeal membrane oxygenation support for 5-fluorouracil-induced acute heart failure with cardiogenic shock. Heart Views. 2014;15(1):26.
- Rateesh S., Shekar K., Naidoo R., Mittal D., Bhaskar B. Use of extracorporeal membrane oxygenation for mechanical circulatory support in a patient with 5-fluorouracil induced acute heart failure. Circ. Hear Fail. 2015;8(2):381-83.
- Tsavaris N., Kosmas C., Vadiaka M., et al. 5-fluorouracil cardiotoxicity is a rare, dose and schedule-dependent adverse event: a prospective study. J. BUON. 2005;10(2):205-11.
- Fontanella C., Aita M., Cinausero M., Aprile G., Baldin M.G., Dusi V. Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients heart? Onco. Targets Ther. 2014;7:1783-91.
- Rateesh S., Luis S.A., Luis C.R., Hughes B., Nicolae M. Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge? Int. J. Cardiol. 2014;172: e331-33.
- Cianci G., Morelli M.F., Cannita K., et al. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity. Br. J. Cancer. 2003; 88:1507-509.
- Ambrosy A.P., Kunz P.L., Fisher G.A., Witteles R.M. Capecitabine-induced chest pain relieved by diltiazem. Am. J. Cardiol. 2012;110: 1623-26.